Cancer Vaccines Market Forecasts to 2028 – Global Analysis By Product Type (Preventive Cancer Vaccines and Therapeutic Cancer Vaccines), Technology (Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Whole-cell Cancer Vaccines and Antigen/

Cancer Vaccines Market Forecasts to 2028 – Global Analysis By Product Type (Preventive Cancer Vaccines and Therapeutic Cancer Vaccines), Technology (Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Whole-cell Cancer Vaccines and Antigen/Adjuvant Cancer Vaccines), Application, End users and By Geography

According to Stratistics MRC, the Global Cancer Vaccines Market is accounted for $7.50 billion in 2022 and is expected to reach $18.95 billion by 2028 growing at a CAGR of 16.7% during the forecast period. Cancer vaccines are drugs that are thought of as biological response modifiers. These biological response modifiers work by boosting the body's immune system's capacity to combat cancer. There are two different kinds of cancer vaccines: therapeutic and preventative. In order to prevent cancer in healthy individuals, preventive cancer vaccines are used. In order to boost their immune systems ability to combat the disease, cancer patients receive therapeutic cancer vaccines. Children and adults alike can receive cancer vaccines intravenously .

According to statistics published by the World Cancer Research Fund (WCRF), there were about 18.1 million cancer cases worldwide in 2020, of which 9.3 million were males and 8.8 million females.

Market Dynamics:

Driver:

Growing strategic partnerships among major market players

The market is characterized by a significant focus on the introduction of novel vaccines by industry players like Merck & Co., Inc., GSK plc, and others. However, a sizable market gap is feared due to a lack of product approvals and an imbalance of therapeutic indications in the pipeline for new vaccines. Additionally, small and mid-size biotech businesses as well as academic institutions working to develop novel cancer vaccines are having trouble finding funding and investments. Therefore, new business models that encourage collaboration are being adopted so that these players can access international markets and provide the market with cutting-edge new products. As a result, a number of mid-sized immunotherapy players involved in the research and development of prophylactic and therapeutic vaccines are now working with well-known companies in the industry to carry out clinical trials to gauge the safety and effectiveness of vaccines.

Restraint:

Limiting the use of cancer vaccines with personalized medicine advances

Cancer, one of the leading causes of death worldwide, is a complex and heterogeneous disease. Therapeutic cancer vaccines target the cancer cells rather than the disease's underlying cause, whereas preventive cancer vaccines work to bolster the body's natural defenses against the disease. Additionally, these vaccines are a form of immunotherapy that only has a small number of cancer types for which they have received global product approval. Based on their molecular subtypes, some cancer types (colon, breast, and non-Hodgkin's lymphoma) have even more detailed classifications. Additionally, the location or stage of the cancer affects how certain markers are expressed within the same tumor. In order to improve the prognosis for these cancer types, more precise treatment methods are required in addition to cancer vaccines. A new approach to prevention and treatment in oncology is personalized or precision medicine. It may alter treatment in ways that target the tumor's oncogenic drivers and influence its environment.

Opportunity:

The expansion of cancer vaccine clinical trials

PDAC, or pancreatic ductal adenocarcinoma, is a common form of pancreatic cancer for which there are no curative therapies. Data from the first phase of a clinical trial for BioNTech's PDAC vaccine against PDAC was made public. The mRNA vaccination developed by BioNTech is used to deliver the genetic code for the neoantigen to the patient's cells. The code instructs the cells to produce the neoantigens, proteins created by cancer cells. These proteins are produced to help the immune system attack the tumor directly.

Threat:

Lengthy regulatory approvals and high developing cost

Market growth is anticipated to be constrained during the forecast period due to the high cost of developing cancer vaccines and the prolonged time required for vaccine manufacturing. Additionally, a sizable market gap is threatened by a lack of product approvals and an imbalance of therapeutic indications in the pipeline of upcoming vaccines.

Covid-19 Impact:

On January 30, 2020, the World Health Organization (WHO) declared the COVID-19 outbreak a public health emergency of global concern. A total of 210 countries around the world have been impacted by COVID-19. Due to closures in several COVID-19-affected countries and an increase in the number of sick healthcare workers following the COVID-19 pandemic, which resulted in a shortage, companies that manufacture and distribute cancer vaccines have only been minimally impacted by COVID-19.

The creavax segment is expected to be the largest during the forecast period

CreaVax is expected to expand significantly during the forecast period. The patient's peripheral blood mononuclear cells (PBMC) are used to make the autologous dendritic cell-based cancer vaccine, which is sensitized with tumor lysate and KLH before maturing into dendritic cells (Keyhole Limpet Hemocyanin). Creagene released Creavax, a therapeutic vaccine for renal cell carcinoma. The effectiveness of CreaVax in the treatment of hepatocellular carcinoma is currently being studied in a Phase III clinical trial.

The adult vaccines segment is expected to have the highest CAGR during the forecast period

The adult vaccine market segment had the largest market share. Additionally, a large number of researchers around the world are conducting in-depth research to develop efficient vaccine candidates to realize potential therapeutic strategies. For instance, Northwest Biotherapeutics of Maryland will announce in March 2022 the start of production of the first personalized dendritic cell-based cancer vaccine at its new production facility in Sawston, UK, using advanced therapy medicinal products for the treatment of a glioblastoma case on compassionate grounds.

Region with highest share:

The largest revenue share came from North America. The factors driving the market during the forecast period include the rising incidence of cancer, rising research expenditures, an increase in clinical trials by industry participants, and regulatory approvals for cancer vaccines. For instance, the American Cancer Society predicts that in 2021 there will be 608,570 cancer deaths in the United States and an estimated 1.9 million new cancer cases. In contrast, the number of Americans who will receive a cancer diagnosis in 2022 will be close to 1.9 million. Breast cancer will be the most common cancer diagnosis in 2018, affecting an estimated 287,850 women and 2,710 men. The most frequent cancer diagnosis in men and the second most frequent overall is prostate cancer.

Region with highest CAGR:

Europe's market is expected to grow significantly. This can be attributed to factors such as the rising demand for cancer vaccines, the rising incidence of cancer, the increase in support for research studies from cancer societies across Europe, and emerging market players in the area, all of which have a positive impact on the market for dendritic cell cancer vaccines.

Key players in the market

Some of the key players in Cancer Vaccines market include Aduro Biotech Inc., Advaxis Inc., Amgen Inc., Argos Therapeutics, Astellas Pharma Inc., Astrazeneca Plc., Batavia Bioservices, Bristol-Myers Squibb Company, Csl Limited, Dandrit Biotech, Dynavax Technologies Corporation, Generex Biotechnology Corporation, Immunocellular Therapeutics, Ltd, Merck & Co., Inc., Sanpower Corporation, Sanpower Group Co. Ltd. And Vaccinogen, Inc.

Key Developments:

In June 2022, Treos Bio Limited, a biotechnology company, announced the first patient dosed in a phase 2 trial of polypepi1018 in combination with pd-l1-inhibitor manufactured by F. Hoffmann-La Roche AG for the treatment of metastatic colorectal cancer.

In October 2020, Vaccibody AS, a clinical-stage biopharmaceutical company, announced its worldwide license and collaboration agreement with Genentech, Inc., a member of the Roche Group, for the development and commercialization of DNA-based individualized neoantigen vaccines (DNA cancer vaccines) for the treatment of cancers.

In June 2020, UbiVac, Inc. announced a clinical trial collaboration with Bristol Myers Squibb to evaluate the safety, tolerability, and preliminary efficacy of UbiVac's investigational product, DPV-001, in combination with Immunotherapy for Advanced Triple Negative Breast Cancer.

Product Types Covered:
• Preventive Cancer Vaccines
• Therapeutic Cancer Vaccines

Technologies Covered:
• Dendritic Cells (DC) Cancer Vaccines
• Recombinant Cancer Vaccines
• Whole-cell Cancer Vaccines
• Antigen/Adjuvant Cancer Vaccines
• Viral Vector & DNA Cancer Vaccines
• Subunit Vaccines
• Conjugate Vaccines
• Inactivated Vaccines
• Live Attenuated Vaccines
• Other Technologies

Applications Covered:
• Prostate Cancer
• Cervical Cancer
• Other Applications

End Users Covered:
• Pediatrics
• Adults
• Other End users

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements